Print 25 January 2016
Powerful cloud-based platform facilitates global collaborations with pharmaceutical companies seeking to develop more precise clinical interventions
SAN FRANCISCO--(BUSINESS WIRE)-- Station X, Inc., a pioneer in solving big data analytics and platform integration challenges for customers engaging in genomics-based clinical research and medical applications, today announced that Epic Sciences will use its GenePool® platform to facilitate data interpretation and collaboration with biopharmaceutical companies developing companion diagnostics based on the company’s innovative circulating tumor cell (CTC) technology.
Currently, Epic Sciences is involved in more than 58 active clinical trials with over 35 pharma partners developing diagnostic assays to target therapies to the right patient population at the right time, which is the ultimate goal of precision medicine. The company is also actively involved in several research collaborations to better understand metastatic disease heterogeneity across multiple disease indications and therapeutic settings.
“Epic Sciences is working closely with biopharmaceutical companies who are interested in developing new diagnostic tests utilizing our proprietary CTC platform to provide insight into heterogeneous metastatic disease at the single cell level. This will elucidate how a patient's cancer evolves over time and the impact on therapeutic efficacy,” said Mark Landers, Director of Genomics at Epic Sciences. “GenePool from Station X delivers a sophisticated data management and collaboration platform that is allowing us to deliver on our strategy to develop a robust commercial platform with a strong and diverse pipeline of diagnostic and companion diagnostic products.”
GenePool from Station X is a secure software-as-a-service platform that makes big genomics data manageable and meaningful. GenePool is pre-loaded with standard clinical reporting capabilities for incidental findings and tumor profiling, but its flexibility means organizations like Epic Sciences can customize GenePool for use with their proprietary assays. GenePool also provides a convenient and dynamic way to share data with collaborators for updated reporting and for the interactive investigation of the aggregated information in an intuitive and secure web-based environment.
“GenePool was developed from the ground up to be a modern and scalable solution that is adaptable to multiple data types and can be customized to support a variety of biomarker discovery applications,” said Shikha O’Brien, Vice President, Commercial Operations at Station X. “We are pleased to be working with innovators like Epic Sciences and proud that GenePool is helping them rapidly deliver insights into disease heterogeneity, simplify the logistical issues involved in dealing with big genomic data and its integration into multi-parametric analysis.”
GenePool is available as a web-based service directly from Station X. Through a flexible API, GenePool will integrate with existing LIMS systems and leading third-party data storage and management platforms including Amazon Web Services, DNAnexus, Google Cloud Platform and Illumina BaseSpace, among others. For more information on GenePool, please visitwww.stationxinc.com.
About Station X
Station X is a leading provider of cloud-based enterprise software solutions that are being used to solve big data analytics and platform integration challenges for customers utilizing genomic data in clinical research and medical applications. GenePool, our flagship product, provides a secure modern architecture that enables secure collaboration and streamlines the delivery of medically relevant insights via innovative solutions for managing and interpreting complex data. Leading academic and commercial organizations around the world are relying on Station X to help them deliver next-generation precision medicine solutions. For more information please visit www.stationxinc.com.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences’ mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences’ no cell left behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences’ goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
25 September 2017
25 September 2017